| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.EJCA.2010.02.049 |
| P698 | PubMed publication ID | 20335017 |
| P2093 | author name string | Qi Yu | |
| Zhe-Yi Hu | |||
| Yuan-Sheng Zhao | |||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meta-analysis | Q815382 |
| diarrhea | Q40878 | ||
| P304 | page(s) | 1856-1865 | |
| P577 | publication date | 2010-03-23 | |
| P1433 | published in | European Journal of Cancer | Q332260 |
| P1476 | title | Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis | |
| P478 | volume | 46 |
| Q64062244 | A Systematic Review of Phytochemistry, Pharmacology and Pharmacokinetics on Radix: Implications for Radix as a Personalized Medicine |
| Q62835353 | A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients |
| Q53105272 | A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients. |
| Q89867978 | An Epileptic Patient with Recurrent Hyperbilirubinemia Caused by Gilbert Syndrome |
| Q34629650 | Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians |
| Q37712297 | Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians |
| Q45590471 | Association of insertion-deletions polymorphisms with colorectal cancer risk and clinical features. |
| Q37055326 | CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel |
| Q33427471 | Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial |
| Q36427498 | Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting |
| Q34274096 | Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer |
| Q41773169 | Clinical usefulness of testing for UDP glucuronosyltransferase 1 family, polypeptide A1 polymorphism prior to the inititation of irinotecan-based chemotherapy |
| Q43358640 | Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype. |
| Q44351944 | Distribution of uridine diphosphate glucuronosyltransferase 1A polymorphisms and their role in irinotecan-induced toxicity in patients with cancer |
| Q38016943 | Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis |
| Q52362144 | Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics. |
| Q55323463 | Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors. |
| Q38922471 | Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. |
| Q34715481 | Metabolic pathways of the camptothecin analog AR-67 |
| Q82473615 | Pharmacogenetic risk for adverse reactions to irinotecan in the major ethnic populations of Singapore: regulatory evaluation by the health sciences authority |
| Q34008793 | Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years |
| Q28068930 | Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use |
| Q37339628 | Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer |
| Q33419875 | Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma |
| Q33604248 | Polymorphisms of uridine glucuronosyltransferase gene and irinotecan toxicity: low dose does not protect from toxicity |
| Q37969770 | Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer |
| Q87163239 | Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with i |
| Q35887458 | Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens |
| Q36975047 | Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms |
| Q36990461 | Significance of Kampo, traditional Japanese medicine, in supportive care of cancer patients |
| Q38202816 | The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis |
| Q33428367 | The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer |
| Q38005612 | The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens |
| Q37731433 | Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis. |
| Q38787385 | UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis |
| Q43525854 | Unconjugated hyperbilirubinemia: a blessing in disguise? |
| Q53082813 | Weekly EZN-2208 (PEGylated SN-38) in combination with bevacizumab in patients with refractory solid tumors. |
Search more.